Talphera (TLPH) Total Liabilities (2010 - 2026)
Talphera (TLPH) posted Total Liabilities of $12.4 million for Q2 2026, up 6.19% on a QoQ basis from $11.7 million in Q1 2026, and up 25.4% year-over-year from $9.9 million in Q2 2025.
Analysis
Talphera (TLPH) Total Liabilities (2010 - 2026) Analysis & Trends
Talphera has reported Total Liabilities for 17 years, with the latest figure at $12.4 million in Q2 2026.
- On a quarterly basis, Total Liabilities rose 25.4% year-over-year to $12.4 million in Q2 2026; TTM through Jun 2026 was $12.4 million, a 25.4% increase from a year earlier, with the FY2025 full-year figure at $12.7 million, up 23.93% from the prior year.
- Total Liabilities was $12.4 million for Q2 2026 at Talphera, up from $11.7 million in the prior quarter.
- The five-year high for Total Liabilities was $110.2 million in Q1 2022, with the low at $5.0 million in Q3 2023.
- Average Total Liabilities over 5 years is $18.0 million, with a median of $11.9 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities slumped 89.07% in 2023, then jumped 129.57% in 2024.
- Over 5 years, Total Liabilities stood at $25.7 million in 2022, then sank by 75.5% to $6.3 million in 2023, then jumped by 62.72% to $10.2 million in 2024, then gained by 23.93% to $12.7 million in 2025, then declined by 2.24% to $12.4 million in 2026.
- The last three Total Liabilities figures came in at $12.4 million (Q2 2026), $11.7 million (Q1 2026), and $12.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 12.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.40 Mn |
| Mar 31, 2026 | 11.68 Mn |
| Dec 31, 2025 | 12.68 Mn |
| Sep 30, 2025 | 11.57 Mn |
| Jun 30, 2025 | 9.89 Mn |
| Mar 31, 2025 | 9.40 Mn |
| Dec 31, 2024 | 10.24 Mn |
| Sep 30, 2024 | 11.37 Mn |
| Jun 30, 2024 | 12.13 Mn |
| Mar 31, 2024 | 12.44 Mn |
| Dec 31, 2023 | 6.29 Mn |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | 7.31 Mn |
| Mar 31, 2023 | 12.05 Mn |
| Dec 31, 2022 | 25.67 Mn |
| Sep 30, 2022 | 20.77 Mn |
| Jun 30, 2022 | 22.99 Mn |
| Mar 31, 2022 | 110.24 Mn |
| Dec 31, 2021 | 113.79 Mn |
| Sep 30, 2021 | 115.28 Mn |